|
Age (≤50/ >50 years)
|
86/175
|
39/63
|
0.379
|
|
Size (≤20/ 21-50/ >50 mm)
|
147/106/5
|
38/56/8
|
<0.001
|
|
Grade (I / II / III)
|
38/95/125
|
10/29/63
|
0.028
|
|
Involved lymph node (-ve/+ve)
|
165/93
|
41/61
|
<0.001
|
|
ER status (no/yes)
|
119/139
|
52/50
|
0.406
|
|
PR status (no/yes)
|
137/121
|
57/45
|
0.634
|
|
HER2 status (no/yes)
|
211/47
|
78/24
|
0.254
|
|
Tumour recurrence (no/local/distant/both)
|
213/7/36/2
|
58/10/31/3
|
<0.001
|
|
Endocrine therapy (no/yes)
|
191/63
|
81/18
|
0.184
|
|
Chemotherapy (no/yes)
|
158/96
|
51/48
|
0.067
|
|
Alive/cancer death/non cancer death
|
148/54/56
|
41/43/18
|
0.158
|
|
Cancer specific survival (months)a
|
178(171–188)
|
138(121–155)
|
<0.001
|
|
Node-negative patients (n = 206)
|
n = 165(80%)
|
n = 41(20%)
| |
|
Age (≤50/ >50 years)
|
51/114
|
16/25
|
0.322
|
|
Size (≤20/ 21-50/ >50 mm)
|
103/60/2
|
17/22/2
|
0.008
|
|
Grade (I / II / III)
|
29/60/76
|
5/13/23
|
0.233
|
|
ER status (no/yes)
|
40/53
|
32/29
|
0.252
|
|
PR status (no/yes)
|
47/46
|
34/27
|
0.529
|
|
HER2 status (no/yes)
|
138/27
|
30/11
|
0.123
|
|
Endocrine therapy (no/yes)
|
118/46
|
31/9
|
0.479
|
|
Chemotherapy (no/yes)
|
113/51
|
29/11
|
0.658
|
|
Tumour recurrence (no/local/distant/both)
|
143/6/15/1
|
27/2/10/2
|
0.001
|
|
Alive/cancer death/non cancer death
|
104/23/38
|
20/12/79
|
0.365
|
|
Cancer specific survival (months)a
|
190(181–199)
|
168(146–190)
|
0.010
|
|
Triple-negative patients (n = 120)
|
n = 85(71%)
|
n = 35(29%)
| |
|
Age (≤50/ >50 years)
|
31/54
|
19/16
|
0.073
|
|
Size (≤20/ 21-50/ >50 mm)
|
49/34/2
|
14/17/6
|
0.025
|
|
Grade (I / II / III)
|
1/14/70
|
0/7/28
|
0.888
|
|
Involved lymph node (-ve/+ve)
|
56/29
|
14/21
|
0.009
|
|
Tumour recurrence (no/local/distant)
|
69/1/15
|
19/2/14
|
0.004
|
|
Endocrine therapy (no/yes)
|
76/8
|
31/4
|
0.754
|
|
Chemotherapy (no/yes)
|
36/48
|
15/20
|
0.999
|
|
Alive/cancer death/non cancer death
|
50/20/15
|
16/17/2
|
0.936
|
|
Cancer specific survival (months)a
|
171(155–187)
|
123(96–150)
|
0.011
|
